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Accepted 9 August 2013AbstractObjective: Since there is no effective curative treatment for Duchenne muscular dystrophy (DMD), prevention mostly depends on genetic
counseling and prenatal diagnosis. About two-thirds of the affected patients have large deletions or duplications, which can be detected by
multiplex ligation-dependent amplification (MLPA). The remaining cases include small mutations, which cannot be easily identified by routine
techniques. In such cases, linkage analysis may be a useful tool for prenatal diagnosis. Here we compared results obtained from linkage using
short tandem repeats (STRs) with those by MLPA and sequencing analysis.
Materials and methods: Eight Vietnamese pregnant women at risk of having a baby with DMD and requesting prenatal diagnosis were recruited
in this study. MLPA and direct sequencing were applied to screen large rearrangements and point mutations in the dystrophin gene in the DMD
probands and the fetal samples. STR linkage was also performed to analyze fetal mutation status.
Results: By MLPA and sequencing analysis, five DMD patients showed deletions of the dystrophin gene, and no deletions of exons were detected
in seven amniotic fluid cell samples; one patient harbored the out-of-frame small deletion of exon 43, which was also found in the fetal sample of
this family. STR analysis revealed the transmission of a mutant allele inside each family.
Conclusion: Our results suggest that the combination of STR and MLPA could be a rapid, reliable, and affordable detection protocol for
determination of the carrier’s status and prenatal diagnosis of DMD in a developing country such as Vietnam.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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The dystrophinopathies encompass a spectrum of muscle
diseases caused by mutations in the DMD gene, which en-
codes the protein dystrophin (OMIM 300377, Online Men-
delian Inheritance in Man) [1]. The severe end of the spectrum
includes progressive muscle diseases that are classified as
Duchenne (DMD, OMIM 310200) or the allelic milder Becker
muscular dystrophy (BMD, OMIM 300376) when skeletal* Corresponding author. Center for Gene and Protein Research, Hanoi
Medical University, 1st Ton That Tung Street, Hanoi 10000, Vietnam.
E-mail address: tranvankhanh@hmu.edu.vn (V.-K. Tran).
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http://dx.doi.org/10.1016/j.tjog.2013.10.014muscle is primarily affected and as Duchenne muscular dys-
trophy (DMD) associated dilated cardiomyopathy when the
heart is primarily affected. The inheritance is X-linked
recessive; while both sexes can carry the mutation, females
rarely exhibit signs of the disease.
DMD is the most frequent inherited muscle disease in
children, affecting around one in 3500 boys [2,3]. DMD is
characterized by progressive muscle weakness, tissue inflam-
mation, replacement of healthy muscle with fibro-fatty tissue,
and muscle wasting with contractures [4]. Typically, all DMD
patients are wheelchair bound in their early teens and few
survive beyond the third decade, with respiratory complica-
tions and cardiomyopathy being common causes of death.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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the molecular mechanism of the disease has been extensively
investigated and many attempts have focused on treatment at
the molecular level, including gene transfer, cell therapies,
exon skipping, and stop codon mutation suppression [5,6].
Nevertheless, a curative treatment for DMD patients is not
likely to be achieved in the near future. Therefore, genetic
counseling and targeted prenatal diagnosis will still be a
cornerstone of the DMD family management in the foresee-
able future.
Identifying the dystrophin mutation in all DMD cases would
permit a molecular diagnosis as the basis for proper genetic
counseling. However, the enormous size of the dystrophin gene
and a large variety of mutations are two major challenges for
the clinical molecular diagnostic laboratory [7]. The dystrophin
gene, located at locus Xp21.1, is the largest human gene
identified, spanning more than 24 Mb of genomic DNA. Dys-
trophin consists of 79 exons, forming a 14-kb mRNA tran-
script, and has lengthy introns (up to 250 kb) [8]. The majority
of identified mutations are deletions, accounting for approxi-
mately 60e65% of DMD cases, and duplications have been
observed in 8e15% [9,10]. The remaining cases include small
mutations, such as microdeletions, microinsertions, point mu-
tations, or splicing mutations [9].
The standard molecular genetic protocol for detection of
deletion and duplication in the dystrophin gene is, nowadays,
by multiplex ligation-dependent probe amplification (MLPA).
It is considered to be the most powerful single technology to
identify gross rearrangements in the large dystrophin gene
[9,11,12]. Point mutation detection has been improved by the
availability of techniques, such as denaturing gradient gel
electrophoresis, protein truncation test, Sanger sequencing,
and next generation sequencing [13e15]. However, these
methods are too labor intensive, time consuming, and expen-
sive for a developing country to be applied in prenatal diag-
nosis of DMD within a few days. Linkage analysis, based on
short tandem repeats (STRs) at polymorphic loci in the dys-
trophin gene, is a rapid method and can be widely used for
carrier detection and in the prenatal diagnosis of DMD fam-
ilies in which the causative mutations cannot be or were not
determined in the probands [16e18].
In this study, we compared STR analysis results with those
of MLPA and sequencing in eight Vietnamese pregnant
women at risk of having a child with DMD, requesting pre-
natal diagnosis to establish a reliable and convenient prenatal
diagnosis protocol for Vietnamese DMD families.
Materials and methodsPatientsGenetic analysis was performed in six unrelated Viet-
namese DMD families including eight pregnant women at risk
of having an affected baby. The family histories were kindly
provided by the Vietnam National Hospital of Pediatrics.
Amniocentesis was performed at 16e22 weeks of gestation
under ultrasound guidance. In this study, all participantssigned a written informed consent as required by the Vietnam
Medical Ethics Council.
In each case, 10 mL of amniotic fluid was taken during
amniocentesis from a pregnant woman. Three to four milliliter
of peripheral blood was collected from all of the DMD pedi-
gree’s relevant members. Genomic DNA was extracted from
the peripheral blood of DMD patients, as well as their family
members, using the QIAamp DNA blood Mini Kit (Qiagen
Inc., Hilden, Germany). The QIAamp DNA Mini kit was used
to extract DNA of the fetal amniotic fluid cells following the
manufacturer’s recommendation. The genomic DNA was
visualized by electrophoresis on a 0.8% agarose gel and
quantified using the Nanodrop system (1000 spectrophotom-
eter, Thermo Scientific, Wilmington, DE, USA).MLPA analysisThe MLPA reaction was performed to screen the dystrophin
gene using the SALSA MLPA probe sets P034 and P035
(MRC-Holland, Amsterdam, The Netherlands) according to
the manufacturer’s instructions. Briefly, 50e100 ng of
genomic DNA in 5 mL deionized water was denatured and
hybridized overnight with the probe mix P034 or P035.
Ligation was performed with Ligase 65 enzyme and finally,
polymerase chain reaction (PCR) amplification was performed
with the specific SALSA FAM PCR primers. Amplification
products and Size Standard 600 were mixed completely and
run by capillary electrophoresis on the Beckman CEQ-8000
genetic analytic system (GenomeLab GeXP, Genetic Anal-
ysis System, Beckman Coulter, Brea, CA, USA). The peaks
obtained after capillary electrophoresis were analyzed by the
GeneMapper v3.2 software (GeneMarker, Softgenetics, LLC
State College, PA, USA).Sequencing analysisPCR amplification of all 79 exons and eight promoters of
the dystrophin gene were performed using Takara Ex Taq DNA
Polymerase (Takara Inc, Otsu, Shiga, Japan). The sequence of
the primers and the respective annealing temperatures for PCR
were obtained from the Leiden Muscular Dystrophy website
(www.dmd.nl, Center for Human and Clinical Genetics, Lei-
den University Medical Center). In total, 87 segments of size
ranging from 170 to 600 base pairs were amplified.
Purified PCR products were subjected to cycle sequencing
with the ABI Bigdye Terminator V1.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA). The purified
products were then sequenced on an ABI PRISM 3100 Ge-
netic Analyzer (Model 373A, Applied Biosystems, Foster
City, CA, USA).STR analysisFour dystrophin intragenic STRs (DSTR44, DnSTR44,
DSTR49, DSTR50) were amplified using the Mastermix and
the previously reported primer oligonucleotides (Leiden
Muscular Dystrophy website). The forward primers were
Fig. 1. Pedigree of family IA and VA.
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actions were performed with the denaturation at 95C for
4 minutes, 35 cycles of denaturation at 95C for 30 seconds,
annealing at 58C for 30 seconds, extension at 72C for
30 seconds, and final extension 72C for 7 minutes. PCR
products (0.5 mL) were mixed with 0.3 mL SS600 and 32 mL
SLS. The mixture was separated by capillary gel electropho-
resis (15 kV at 60C for 30 minutes) on Beckman CEQ-8000
genetic analytic system. The data was then analyzed with
GeneMapper v3.2 software.
ResultsMLPA analysis resultsMLPAwas performed in six DMD patients for the deletion
and duplication diagnosis. Five patients showed deletions of
the dystrophin gene (case IA, IIA, IIIA, IVA, VIA, Fig. 1,
Table 1). In all mothers of the affected patients, MLPA anal-
ysis determined their carrier status as the signal of the mutated
exons was about half that of the control value.
The fetal gender was rapidly determined by SRY gene
detection in the amniotic fluid samples of eight pregnant
women. All cases were found to be male and required further
prenatal diagnosis for DMD.
For seven pregnant women belonging to families in which
the proband had a deletion, MLPA was applied to detect po-
tential deletion. The analysis results showed that no deletion of
exons was detected in seven fetal amniotic fluid cell samples:Table 1
Mutation characteristics of the dystrophin gene detected in Duchenne muscular dy
DMD patients/family Mutation detected Pregnant woman at
I/IA Del. Ex11e39 23
II/IIA Del. Ex44 30 and 32
III/IIA Del. Ex46e50 39
IV/IVA Del. Ex3e8 20
V/VA 6213_6214 del. CC 12
VI/VIA Del. Ex8e12 9 and 10
Del. ¼ deletion; Ex ¼ exon; MLPA ¼ multiplex ligation-dependent probe amplifithese fetuses were diagnosed as non-affected within 1 week of
sampling.Sequencing analysis resultsOne proband who did not show any deletion or duplication
was analyzed by direct sequencing. Sequencing of exon 43
showed a novel 2 bp deletion (6213_6214 delCC) (Fig. 3),
causing a frameshift mutation. His mother was a carrier as the
sequencing analysis was found to harbor a 2 bp heterozygous
deletion. Exon 43 of the dystrophin gene was also sequenced
in the fetal DNA (case VA - at the 21st week of pregnancy),
and the 2 bp deletion was again found: the fetus was thus
diagnosed as affected after 3 weeks from sampling.STR analysis resultsThe STR analysis results clearly showed that the genomic
DNA from amniotic fluid cells used in all experiments was not
significantly contaminated by DNA from their mothers.
In all cases, it could be reasonably determined which alleles
of the mother harbored the mutant dystrophin gene. In five
cases (IA, IIA, IIIA, IVA, VIA), the fetuses inherited their
mother’s normal allele and were thus diagnosed as non-
affected, whereas in case VA, the fetus inherited the
mother’s mutant allele and was diagnosed as affected. The
STR analysis required 1 week to run and interpret and showed
results consistent to those of MLPA or sequencing. Two
analysis results of typical DMD families in this series are
illustrated in Figs. 2 and 3.Discussion
DMD is an X-linked, inherited neuromuscular disease
characterized by a relatively high incidence and lethality rate.
Currently, there is no effective treatment for DMD patients;
therefore, the mainstay of prevention is detection of female
carriers and diagnosis of affected fetuses. Performing prenatal
diagnosis can provide sufficient and valuable genetic infor-
mation that allows DMD families to make appropriate repro-
ductive choices. The best strategy for a comprehensive DMD
prenatal diagnosis depends on the realistic circumstances of
each country. A balance must be found between diagnostic
accuracy, costs of initial mutation detection, and the timestrophy (DMD) patients.
risk no. Prenatal diagnosis results
By MLPA and sequencing By STR analysis
Non affected Inherited normal allele
Non affected Inherited normal allele
Non affected Inherited normal allele
Non affected Inherited normal allele
Affected Inherited mutant allele
Non affected Inherited normal allele
cation; STR ¼ short tandem repeat.
Fig. 2. Multiplex ligation-dependent probe amplification (MLPA) and short tandem repeat (STR) analysis results of family IA. These MLPA-SALSA probe mix
P034 showed deletion of exon 21e30 of the dystrophin gene in the proband and his mother. MLPA showed no deletion of these exons in the fetal amniotic fluid cell
samples. STR analysis indicated that the fetus inherited the mother’s normal allele. The fetus was diagnosed as non-affected.
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around time).
Mutation diagnosis for the proband is always the first step
of a standard prenatal diagnosis procedure. In this study, theFig. 3. Sequencing and short tandem repeat (STR) analysis results of family VA. Dir
the proband and the fetus. His mother was a carrier as the sequencing analysis was
fetus inherited the mother’s mutant allele. The fetus was diagnosed as affected.MLPA technique was applied to screen large rearrangements
of the dystrophin gene in DMD probands. No duplication, but
five deletions were identified, including one case (patient IIA)
harboring a single deletion of exon 44 (Table 1). Recently, Leeect sequencing of exon 43 showed a novel 2 bp deletion (6213_6214 delCC) in
found to harbor a 2 bp heterozygous deletion. STR analysis indicated that the
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positive MLPA result due to the presence of the nucleotide
change obstructing probe annealing. A confirmatory experi-
ment by monoplex PCR was performed to eliminate this
possibility in our case, as the PCR result reconfirmed the
single deletion of exon 44 of patient IIA (data not shown).
Deletion can happen almost anywhere in the dystrophin gene.
However, one location towards the central part of the gene
(exons 44e55) and the other site towards the 50 end (exons
2e20) have been previously reported as the two hot-spot re-
gions [20,21]. Our data are in agreement with those studies.
We also apply the MLPA technique for the carrier detection in
DMD families; MLPA analysis determined the carrier status of
seven pregnant women as the signals of the mutated exons
were about half the value of controls. Only 2e3 days were
required to perform MLPA analyses and interpret the results.
For the patient with no deletion or duplication on MLPA
(patient VA), full sequence analysis showed a novel 2-bp
deletion (6213_6214 delCC) causing a frameshift mutation
of the dystrophin gene. His mother was a 2-bp heterozygous
deletion carrier as determined by sequencing analysis. The
mutation was also found in the fetal DNA; the sequencing
analysis required 3 weeks to identify the mutation and inter-
pret prenatal diagnosis results. This amount of time illustrated
the fact that full exon sequencing was time consuming and too
costly.
It is important to note that one of the most common causes
of diagnostic errors is due to the contamination of amniotic
fluid by maternal blood cells at amniocentesis, which could
lead to the amplification of the maternal gene and result in a
false positive. This problem can be controlled by carrying on
the STR analysis. Besides that, the linkage analysis could
identify the transmission of the mutant allele inside each DMD
families in which the (CA)n STR in the 30 end loci of intron 44
and 49 was amplified using fluorescent PCR. In five of our
DMD families (IA, IIA, IIIA, IVA, VIA), it can be reasonably
inferred that the maternally inherited X chromosome of the
fetuses comes from the mother’s normal X chromosome, while
the fetus in family VA received his mother’s mutant X chro-
mosome. STR analysis produced results in agreement with
those obtained by MLPA or sequencing, but required much
less time to conduct. From our experience, STR analysis is fast
(PCR was amplified in w2.5 hours, and the capillary gel
electrophoretic run tookw30 minutes), accurate, inexpensive,
and easy to perform. However, the linkage analysis should not
be applied as the only technique in every case of prenatal
diagnosis, due to the high recombination rate of the dystrophin
gene. Some previous studies reported that intragenic recom-
bination in the dystrophin gene has been shown to occur with a
frequency as high as 10e12% [22e24], which illustrates the
limitation of linkage analysis for prenatal diagnosis of DMD.
In summary, our study showed that a combined strategy
that includes MLPA and STR analysis could minimize diag-
nostic errors in linkage analysis and offer advantages over the
approach of MLPA or sequencing alone. This combination
may become a method of choice in Vietnam for prenatal
diagnosis in familial cases of DMD.Acknowledgments
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